0R31 Stock Overview
Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 1/6 |
Past Performance | 5/6 |
Financial Health | 2/6 |
Dividends | 6/6 |
Altria Group, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$43.56 |
52 Week High | US$46.69 |
52 Week Low | US$39.27 |
Beta | 0.70 |
1 Month Change | 4.88% |
3 Month Change | 8.02% |
1 Year Change | -6.57% |
3 Year Change | -12.89% |
5 Year Change | -15.59% |
Change since IPO | 206.55% |
Recent News & Updates
Recent updates
Shareholder Returns
0R31 | GB Tobacco | GB Market | |
---|---|---|---|
7D | -1.1% | 0.2% | 0.7% |
1Y | -6.6% | -13.4% | 3.0% |
Return vs Industry: 0R31 exceeded the UK Tobacco industry which returned -13.4% over the past year.
Return vs Market: 0R31 underperformed the UK Market which returned 3% over the past year.
Price Volatility
0R31 volatility | |
---|---|
0R31 Average Weekly Movement | 2.7% |
Tobacco Industry Average Movement | 2.9% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.4% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0R31 has not had significant price volatility in the past 3 months.
Volatility Over Time: 0R31's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1822 | 6,400 | Billy Gifford | www.altria.com |
Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company offers cigarettes primarily under the Marlboro brand; large cigars and pipe tobacco under the Black & Mild brand; moist smokeless tobacco and snus products under the Copenhagen, Skoal, Red Seal, and Husky brands; oral nicotine pouches under the on! brand; and e-vapor products under the NJOY ACE brand.
Altria Group, Inc. Fundamentals Summary
0R31 fundamental statistics | |
---|---|
Market cap | US$74.70b |
Earnings (TTM) | US$8.45b |
Revenue (TTM) | US$20.46b |
8.8x
P/E Ratio3.7x
P/S RatioIs 0R31 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0R31 income statement (TTM) | |
---|---|
Revenue | US$20.46b |
Cost of Revenue | US$6.25b |
Gross Profit | US$14.21b |
Other Expenses | US$5.75b |
Earnings | US$8.45b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 31, 2024
Earnings per share (EPS) | 4.92 |
Gross Margin | 69.45% |
Net Profit Margin | 41.32% |
Debt/Equity Ratio | -494.5% |
How did 0R31 perform over the long term?
See historical performance and comparison